Lewy Body Dementia Treatment Global Market Report 2024

The lewy body dementia treatment market size has grown strongly in recent years. It will grow from $4.14 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth observed in the historical period can be attributed to various factors, including the provision of supportive care and family education, regulatory approvals and guidelines, the adoption of multidisciplinary care approaches, and the implementation of psychosocial and behavioral interventions.

The lewy body dementia treatment market size is expected to see strong growth in the next few years. It will grow to $5.68 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to advancements in neurology, increased focus on research initiatives, the development of precision medicine and biomarkers, the adoption of collaborative healthcare models, and the expansion of telemedicine. Major trends expected in the forecast period include an emphasis on family and caregiver support, the implementation of integrated care models, personalized treatment approaches, the utilization of non-pharmacological interventions, and the integration of digital health solutions in Lewy body dementia treatment.

The lewy body dementia treatment market is anticipated to witness growth due to the increasing prevalence of brain-related disorders. Brain disorders encompass conditions that impact brain function, ranging from mild to severe impairment depending on the extent of brain damage. Treatments for lewy body dementia aim to address symptoms such as hallucinations, confusion, and drowsiness by enhancing brain chemicals to improve alertness and cognition. A report shared by the American Heart Association Inc. in January 2022 indicated a projected increase in brain disorders to 9.3 million in the US by 2060. Currently, the prevalence of brain disorders is on the rise globally, affecting one in every six people worldwide, with an estimated 1 billion individuals suffering from brain disorders by 2021. This surge in brain-related disorders is a significant driver for the lewy body dementia treatment market.

The growth of the Lewy body dementia treatment market is expected to be propelled by the rising aging population. An aging population signifies a demographic shift characterized by an increasing proportion of elderly individuals within society. Lewy body dementia treatments play a crucial role in managing symptoms, enhancing cognitive function, and improving the quality of life for the aging population affected by this progressive neurodegenerative disorder. According to the World Health Organization's projections in October 2022, by 2030, one out of every six individuals globally will be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion during this period. Moreover, the global population of individuals aged 60 and older is anticipated to double by 2050, reaching 2.1 billion. Consequently, the rising aging population is a significant factor driving the Lewy body dementia treatment market.

Innovation emerges as a key trend in the lewy body dementia treatment market, with major companies focusing on developing innovative solutions to strengthen their market positions. Biogen Inc., a multinational biotechnology company, introduced lecanemab in January 2023. This humanized monoclonal antibody is designed to treat Alzheimer's disease, which is a component of Lewy body dementia. Lecanemab stands out by reducing brain amyloid levels, addressing amyloid plaques believed to contribute to cognitive impairment and dementia in Alzheimer's disease.

Major companies in the lewy body dementia treatment market are also concentrating on providing revolutionary transdermal systems that leverage innovative technology, such as CORPLEX technology for Alzheimer's dementia treatment. Corium, a biopharmaceutical leader in CNS therapies, launched ADLARITY in September 2022. This once-weekly transdermal system delivers donepezil for Alzheimer's patients, addressing the disease component in Lewy body dementia. Utilizing CORPLEX technology, it ensures sustained drug release for enhanced efficacy and reduced gastrointestinal side effects.

In October 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, acquired Biohaven Pharmaceuticals Inc. for $11.6 billion. This strategic acquisition aims to enhance Pfizer's potential to offer new treatment options globally. Biohaven Pharmaceuticals Inc. is a pharmaceutical company focused on developing drugs for the treatment of Parkinson's disease, which is related to Lewy body dementia.

Major companies operating in the lewy body dementia treatment market report are Mallinckrodt Pharmaceuticals Co., BioArctic AB, Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals Inc., Allergan plc, Novartis International AG, Pfizer Inc., Bayer AG, Amneal Pharmaceuticals LLC., Boehringer Ingelheim International GmbH., Merck & Co. Inc., Abbott Ltd., B Braun SE, Biogen Inc., Biohaven Pharmaceutical Holding Company Ltd., BioMarin Pharmaceutical Inc., Blairex Laboratories Inc., Blink Health LLC, Blueprint Medicines Corporation, Bristol Myers Squibb Company, Calliditas Therapeutics AB, Catalyst Pharmaceuticals Inc., Chiesi USA Inc., Clovis Oncology Inc., Coherus Biosciences Inc., CooperSurgical Inc., Covis Pharmaceuticals Inc., Genzyme Corporation, GlaxoSmithKline plc, Eisai Co. Ltd., Bausch Health Companies Inc., Hisamitsu Pharmaceutical Co. Inc., Lundbeck Inc.

North America was the largest region in the Lewy body dementia treatment market in 2023. The regions covered in the lewy body dementia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lewy body dementia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main drug types in the Lewy body dementia treatment market include antidepressants, antipsychotic drugs, benzodiazepines, carbidopa-levodopa, cholinesterase inhibitors, and modafinil. Antidepressants are medications prescribed to treat depression and various related conditions, such as anxiety disorders, obsessive-compulsive disorder (OCD), chronic pain, eating disorders, and post-traumatic stress disorder (PTSD). They work by increasing the levels of certain chemicals in the brain to improve mood. Distribution channels for these treatments include hospitals pharmacies, retail pharmacies, online pharmacies, and others. These treatments are commonly used for conditions such as Alzheimer's disease, dementia, and Parkinson's disease.

The lewy body dementia treatment market research report is one of a series of new reports that provides lewy body dementia treatment market statistics, including lewy body dementia treatment industry global market size, regional shares, competitors with a lewy body dementia treatment market share, detailed lewy body dementia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lewy body dementia treatment industry. This lewy body dementia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.